CADL
NASDAQCandel Therapeutics Inc.
Price$10.17+0.62 (+6.49%)
01:30 PM07:45 PM
News · 26 weeks66+633%
2026-01-182026-07-12
Mix3890d
- Insider16(42%)
- Other10(26%)
- SEC Filings7(18%)
- Analyst2(5%)
- Earnings2(5%)
- Leadership1(3%)
Latest news
25 items- ANALYSTStifel initiated coverage on Candel Therapeutics with a new price targetStifel initiated coverage of Candel Therapeutics with a rating of Buy and set a new price target of $22.00
- INSIDERSEC Form 4 filed by Chief Commercial Officer Sims Mark E.4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sims Mark E.3 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- PRCandel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 6, 2026, the Compensation Committee of Candel’s Board of Directors granted Mark Sims, in connection with his employment as the Chief Commercial Officer of Candel, stock options to purchase an aggregate of 285,000 shares of the Company’s common stock, with a per share exercise price of $10.03, which is equal to the closing price of the Company’s common stock on The Nasdaq Global Market on July 6, 2026. Th
- INSIDERChief Scientific Officer Barone Francesca sold $235,769 worth of shares (23,447 units at $10.06) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 77,362 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERChief Technology Officer Tyagarajan Seshu sold $70,151 worth of shares (7,000 units at $10.02) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 83,865 units (SEC Form 4)4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on June 30, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 25,000 shares of the Company’s common stock, with a per share exercise price of $10.30. The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying th
- PRCandel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint InhibitorsPhase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous, non-small cell lung cancer (NSCLC) with progressive disease despite prior pembrolizumab and platinum chemotherapyGlobal pivotal phase 3 trial expected to enroll patients in 1:1 randomization across more than 150 sites; first site now open for enrollmentPrimary endpoint is overall survivalCandel has engaged Parexel International to support execution of this global pivotal trial NEEDHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NA
- PRCandel Therapeutics Appoints Mark Sims as Chief Commercial OfficerAppointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Mark Sims as the Company’s Chief Commercial Officer, effective July 6, 2026. Mr. Sims will lead Candel’s commercial strategy and launch readiness for aglatimagene besadenovec (aglatimagene or CAN-2409) in interm
- INSIDERSEC Form 4 filed by Director Radhakrishnan Maha4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Loggia Nicoletta4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Papa Joseph C4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Benz Edward J. Jr4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Martell Christopher4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Gaeta Renee4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Nabel Gary J.4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Nguyen Diem4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- INSIDERSEC Form 4 filed by Director Manning Paul B4 - Candel Therapeutics, Inc. (0001841387) (Issuer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- SECCandel Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Candel Therapeutics, Inc. (0001841387) (Filer)
- PRCandel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate CancerPeer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent combined with aglatimagene besadenovec (aglatimagene) plus valacyclovir compared to placebo plus valacyclovirFindings support that addition of aglatimagene to standard-of-care radiotherapy can provide a meaningful benefit without increasing clinically significant toxicity Data reported in this publication will support planned Biologics License Application (BLA) submission for aglatimagene in fourth quarter of 2026 NEEDHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Candel Thera
- PRCandel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NEEDHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on May 31, 2026, the Compensation Committee of Candel's Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 63,000 shares of the Company's common stock, with a per share exercise price of $8.30. The inducement stock options were made under the Company's 2025 Inducement Plan (the Plan) and will vest with respect to 25% of the shares of common stock underlying t
CADL FAQ
7 questionsWhat does Candel Therapeutics Inc. do?
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of cancer immunotherapy drugs. The company offers Gene Mediated Cytotoxic Immunotherapy technology-based drugs that are designed to work with radiation, chemotherapy, and surgery to eradicate residual tumor cells that could lead to recurrence or metastases. Its product candidates include CAN-2409, an off-the-shelf adenovirus product candidate, for the treatment of localized, primary prostate cancer and therapy for pancreatic cancer; and CAN-3110, its HSV product candidate...Where does CADL stock trade?
Candel Therapeutics Inc. (CADL) is listed on NASDAQ.What sector and industry is CADL in?
Candel Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Candel Therapeutics Inc. go public?
Candel Therapeutics Inc. (CADL) completed its IPO in 2021.What are analysts saying about CADL?
Candel Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $2200.00 price target on 2026-07-13. Recent price targets range from $700.00 to $2500.00.What companies are similar to CADL?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare CADL side-by-side with any of them on Quantisnow.How can I track CADL on Quantisnow?
Quantisnow aggregates Candel Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CADL to receive live email and push alerts on every new disclosure.